When "Detox" Becomes an Unapproved Drug
Turning a blocked purchase order into a compliant resubmission.
Easterlies · May 23, 2026 · 5 min read
Summary
Standard Chinese tea marketing phrases like "lowers blood pressure" and "detox" nearly killed a U.S. deal by triggering 'unapproved drug' classifications. Easterlies coordinated a specialist-led rewrite and a comprehensive issue log to make the label compliant and the deal reviewable.
Marketing in one country, a violation in another
The original listing was standard for its home market. Phrases such as 促进消化 (aids digestion), 排毒养颜 (detox and beautify), and 降压 (lowers blood pressure) are common in Chinese e-commerce. The supplier viewed this as fluency-based marketing, not regulatory compliance.
In the U.S., these words change the product's legal identity. Under 21 CFR 101.93, food or dietary ingredients may describe their role in maintaining normal body structure or function. For example, stating that "green tea contains antioxidants that support cell health" is generally permissible.
However, products cannot claim to diagnose, treat, mitigate, cure, or prevent a disease. "Lowers blood pressure" is a direct disease claim; "detox" is often viewed as an implied one. Under Section 201(g)(1)(B) of the FD&C Act, crossing this line reclassifies the product as an unapproved new drug, regardless of the tea's actual safety.
FDA enforcement is frequent. A 2021 warning letter to TeaTaze, LLC cited claims like "fight viruses" and "immunity booster" as evidence of unapproved drug status. A 2018 letter to Get The Tea targeted "Detoxify: Parasites, Bacteria & Toxins" language. The risk follows the language, not the seller's nationality. These regulations are landmines because reasonable people often write this copy without intending to make a drug claim.
Half the claims as written would have turned the product into a drug, and nobody writing the label had been told that rule existed.
The gap between production and regulatory readiness
The factory had strong operational capabilities: a modern facility, basic QA records, and an existing relationship with a U.S. distributor. The failure was the assumption that advertising is a stylistic choice rather than a legal classification. Because the copy was translated for fluency, the supplier did not realize that understated marketing in one system is a violation in another.
The distributor's compliance reviewer caught the error before the purchase order was issued. This temporary halt was the best possible outcome, as shipping this language would have created massive exposure for both parties. Beyond the FDA, the FTC requires "competent and reliable scientific evidence" for health claims, a standard traditional-use testimonials cannot meet.
Systematic mapping via the Issue Log
Instead of immediate rewriting, we built a line-by-line issue log. We captured every claim across labels, packaging, and the website, logging the exact wording, likely classification (structure/function, disease, or ambiguous), and the implicated rule. This was an evidence-mapping exercise to guide the specialist, not a legal opinion.
The process revealed secondary gaps: incorrectly formatted Nutrition or Supplement Facts panels, missing contact information per 21 CFR 101.5, and the lack of a documented allergen review under FALCPA. While minor individually, logging them together provided a complete compliance picture.
The log also clarified why the buyer had escalated the issue. The distributor's supplier questionnaire required a signed label-compliance attestation before a PO could be issued. The claims problem was not a result of buyer caution, but their internal compliance gate functioning as intended.
Specialist-led resolution
Easterlies does not perform claims classification or sign off on legal language. We provided the issue log to a qualified food-labeling consultant, allowing them to start with a structured map rather than a blank label. For claims with severe disease-claim exposure, the specialist referred those items to regulatory counsel.
The specialist determined the correct food-versus-supplement positioning, rewrote the claims, and applied the required DSHEA disclaimer where applicable. Easterlies managed the engagement, briefed the specialist, and helped assemble the final attestation paperwork referencing the specialist's sign-off.
The result was a revised label and marketing package ready for resubmission, featuring compliant language and correct Nutrition Facts formatting. Since the FDA does not pre-clear labels, no one can guarantee the agency will never act; however, the claims were now professionally reviewed and a defensible trail was established. The product remained the same; only the words and the expertise behind them changed.
Scope
- 01 Gap-scoping against buyer standards to confirm the blocker was claims language rather than food safety
- 02 Creation of a line-by-line claims and label issue log for all packaging and marketing materials
- 03 Mapping buyer requirements against the current label to explain the distributor's escalation
- 04 Coordination of a qualified food-labeling consultant and regulatory counsel for high-risk disease-claim exposure
The outcome
The issue log allowed the labeling specialist to pre-classify claims and drastically reduce discovery time. Within the engagement window, a revised label package featuring compliant claims and correct Nutrition Facts formatting was submitted to the buyer. While the final purchasing decision and FDA risk remain with the buyer, the project successfully converted a blocked deal into a reviewable resubmission.
What to take from this
- Ordinary marketing language can legally reclassify a food product as an unapproved drug in the U.S.
- Literal translations of phrases like "detox" and "lowers blood pressure" carry high regulatory risk.
- Distributor compliance attestations catch claims exposure before a Purchase Order is issued.
- Defensibility relies on a qualified specialist's sign-off, supported by a detailed claims issue log.
Easterlies view — The solution isn't guessing at 'safe' language. It's mapping every claim into a structured log so a qualified specialist can classify it efficiently.
Glossary
- Structure/function claim vs. disease claim
- A structure/function claim (e.g., "supports cell health") describes a role in maintaining normal body function and is permitted. A disease claim (e.g., "lowers blood pressure") implies a product diagnoses, treats, or prevents a disease, which is prohibited for food/supplements.
- FD&C Act / unapproved new drug
- The Federal Food, Drug, and Cosmetic Act. Under this law, a product making a disease claim is legally reclassified as an unapproved new drug based on its claims, regardless of actual safety.
- FDA warning letter
- A formal public notice issued by the FDA when a company is believed to be violating the law, requiring corrective action typically within 15 working days.
- DSHEA
- The Dietary Supplement Health and Education Act. It allows supplements to make structure/function claims if they include a mandatory disclaimer stating the FDA has not evaluated the claim.
- FALCPA
- The Food Allergen Labeling and Consumer Protection Act. It requires labels to clearly identify any of the nine major allergens present in the product.